AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05604014 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Health Coach
Description: My Health Coach is a self-directed mobile health intervention for adults with FASD. It is grounded in self-determination theory and integrates well-established behavior change strategies. It has a cloud-based infrastructure and uses a just-in-time adaptive intervention design and a simple and engaging chatbot interface. It provides adults just the right type and amount of support, when they are most receptive.
Study NCT05594355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEBOFORTAN
Description: TEBOFORTAN 240 mg is administrated 1 tablet per day
Study NCT05553938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: Empagliflozin 10mg
Study NCT05553938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Empagliflozin matched placebo tablet
Study NCT06385210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi structured interviews
Description: Participants will be interviewed concerning perceived barriers to routine surgical video recording
Study NCT05730218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONL1204 Ophthalmic Solution
Description: ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
Study NCT05730218 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham injection is performed by touching the eye surface with a syringe without a needle
Study NCT05604287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID119031166M
Description: The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.
Study NCT05604287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participant will receive a oral dose of Placebo.
Study NCT04430335 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone interview
Description: Interested participants will complete a telephone interview to determine eligibility for the study. If found to be eligible for the study, participants will be registered and set up a time to speak with an assigned study coach.
Study NCT04430335 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: Participants will speak with their assigned coach over the phone for 12 weeks to discuss the cognitive behavioral therapy (CBT) study workbook and provide feedback. CBT is a type of treatment that teaches people different ways to handle anxiety and/or depressive symptoms, such as by relaxing the body, changing thoughts, and solving problems. Participants will receive a workbook focused on teaching these strategies.
Study NCT05313893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: Subjects receive two doses of quadrivalent influenzavaccine administered 4 weeks apart by intramuscularinjection. Each 0.5-ml dosecontained 15 μg of hemagglutinin per strain.
Study NCT04530825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-List Control
Description: -Will receive routine clinical care. After completion of follow-up measures, control participants will receive a behavior change prescription via the PREVENT tool
Study NCT04530825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVENT Tool
Description: -PREVENT is a novel Health Information Technology tool designed to promote physical activity and healthy food intake among overweight/obese adolescent patients at the point of care. PREVENT automates the delivery of personalized, evidence-based behavior change recommendations and provides an interactive map of community resources to help providers link patients to resources in their community.
Study NCT04833309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and dosage will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
Study NCT04833309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: The procedure will be implemented to participants twice a week for total 5 weeks. The specific prescription including type and body part will be determined according to the physician's choice, and information will be recorded in the case report form retrospectively.
Study NCT05620862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Description: In phase Ia, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 . In phase Ib, mitoxantrone hydrochloride liposome will be administered by an intravenous infusion of 24mg/m2. Up to 6 cycles (21 days per cycle)
Study NCT05620862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/ m2，d1-5, 21 days per cycle
Study NCT05620862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5mg/ m2，d1 , 21 days per cycle
Study NCT06496243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
Description: 10 mg obicetrapib for 8 weeks followed by 10 mg obicetrapib/ 140 mg evolocumab (every 2 weeks) combination for 8 weeks
Study NCT06542237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YCT-529
Description: In the Phase 1b part of the study, 4 dosing cohorts and one optional 5th cohort with 4 participants will be evaluated (up to 20 participants): 15, 45, 90 and 180 mg. In the Phase 2a part, up to 3 cohorts of up to 10 participants (up to 30 participants) will receive doses within the range of doses that was well tolerated and had biological activity in the Phase 1b portion.
Study NCT05865652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Description: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Study NCT05865652 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Description: Cerebral MRI with Phosphorus 31 Magnetic Resonance Spectroscopy
Study NCT04869683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: description of MDS pzatient cohort
Description: description of MDS patient cohort
Study NCT06188468 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT
Description: Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant D
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant E
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant F
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant G
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide Monohydrate
Description: Tiotropium Easyhaler 10 µg/dose Product variant H
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide Monohydrate
Description: Spiriva 18 µg/capsule inhaled via Handihaler
Study NCT04850144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Easyhaler with oral activated charcoal
Description: The charcoal suspension will be administered orally with Tiotropium Easyhaler 10 µg/dose Product variant F
Study NCT03318952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
Study NCT03318952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine
Description: A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
Study NCT06048874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06048874 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sono-guided injection
Description: After spinal anesthesia, patients will be injected around femoral nerve using ultrasonography.
Study NCT06048874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: After spinal anesthesia, patients will be injected 20ml ropivacaine around femoral nerve.
Study NCT06048874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: After spinal anesthesia, patients will be injected 20ml 0.9% saline around femoral nerve.
Study NCT06009796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Tissue Borne Rapid Palatal Expansion
Description: In all rapid palatal expansion groups, the appliances were cis bonded after being made by the same technician. The expansion screw was turned twice a day until the desired width was achieved.
Study NCT06009796 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth Bone Borne Rapid Palatal Expansion
Description: After the Marpe appliance was attached, 4 miniscrews were applied to the midline of the palate with a miniscrew driver. The expansion screw was turned twice a day until the desired width was achieved.
Study NCT05137093 — intervention group
Intervention type: DEVICE
Intervention: Actigraphy Device
Description: Patients will wear actigraphy device which detects scratching events.
Study NCT06102863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Description: Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with statins (oral atorvastatin calcium tablet 20mg/ day; Or rosuvastatin 5mg/ day; Or pivastatin 2mg/ day);
Study NCT05398497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation will be performed under ultrasound guidance.
Study NCT06266741 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lubricin
Description: Plasma lubricin levels can potentially serve as a biomarker in situations like endocardial injury and infection.
Study NCT06188663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt supplementation (encapsulated sodium chloride)
Description: A high salt intake range will be achieved through unchanged dietary intake and supplementary salt in the form of 1.25g sodium chloride capsules at a dose of 5g/day in two divided doses
Study NCT05540717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PQ Grass
Description: Suspension for Injection
Study NCT05540717 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection
Study NCT05781386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM1811-03 or in combination with Sintilimab injectiont
Description: SIM1811-03 is a first-in-class igG-1 based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumor.~Sintilimab is an IgG4 humanized monoclonal antibody against programmed cell death protein 1 (PD-1)
Study NCT05321914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise will consist of 1 set x 9 exercises x 3 sessions per week x 6 weeks. The load to be used during training will be calculated as 80% of one-repetition maximum (1RM) with each set performed to failure. 1RM will be re-tested on week 3, and the load adjusted accordingly, and upon completion of the study. During the training period, all sessions of training will be supervised by the researcher. The following exercises will be performed: Bench press, biceps curl, lat pull down, overhead press, lateral raise, leg extension, leg curl and calf raise.
Study NCT04902170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge pars plana vitrectomy
Description: 25 gauge pars plana vitrectomy
Study NCT04902170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25 gauge pars plana vitrectomy
Description: 25 gauge pars plana vitrectomy
Study NCT06311929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody and lenvatinib
Description: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months.
Study NCT06311929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 monoclonal antibody
Description: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.
Study NCT06404554 — intervention group
Intervention type: OTHER
Intervention: without any intervention
Description: without any intervention
Study NCT05240586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and volume of pharmacopuncture according to participants' conditions.
Study NCT05240586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture therapy
Description: This is a pragmatic RCT, so the physicians will choose the type and number of acupuncture therapy according to participants' conditions.
Study NCT05862805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sample Collection and Endometrial Biopsy
Description: Participants will provide daily samples of menstrual blood for a single cycle and undergo a single endometrial biopsy for HEEC culture.
Study NCT05054777 — intervention group
Intervention type: PROCEDURE
Intervention: oncoplastic breast-conserving surgery
Description: The patients received oncoplastic breast-conserving surgery, including volume displacement or volume replacement techniques
Study NCT05054777 — intervention group
Intervention type: PROCEDURE
Intervention: conventional breast-conserving surgery
Description: conventional breast-conserving surgery without any oncoplastic operations
Study NCT04824872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, low dose
Study NCT05270499 — intervention group
Intervention type: DEVICE
Intervention: Aveir VR Leadless Pacemaker System
Description: This study will utilize real-world data from patients implanted with the Aveir VR Leadless Pacemaker System. No device intervention will be conducted in this study.
Study NCT05845723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Participants will receive intravenous infusion of tocilizumab 8mg/kg every 4 weeks for 24 weeks.
Study NCT05845723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tofacitinib
Description: Participants will receive tofacitinib 5mg twice a day for 24 weeks of treatment.
Study NCT05845723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Participants will receive intravenous infusion of cyclophosphamide 0.5g biweekly for 24 weeks.
Study NCT06485284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: El Camino
Description: El Camino is a goal-setting sexual health promotion program. El Camino's lessons and activities:~* Are anchored in sexual health promotion and goal-setting~* Incorporate a goal achievement model throughout the curriculum~* Are designed with a focus on the needs of Latino youth~* Focus on the most effective forms of contraception, including long-acting reversible contraceptives~The El Camino curriculum contains eleven 45-minute lessons and is divided into three sections, or arcs. The three arcs focus on goal setting, sexual and reproductive health, and healthy relationships.
Study NCT06485284 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life skills program
Description: Youth enrolled in the control condition will receive one of several curricula focused on life skills or leadership, depending on the site and implementation period. These curricula include PODER, an 11-session curriculum that focuses on youth leadership development; Youth Encuentros, a psychoeducational curriculum focused on mental health; El Joven Noble, a youth leadership curriculum; and Courageous Queens, a socio-emotional and character strengthening curriculum.
Study NCT06235970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (tES) including SHAM
Description: Transcranial electrical stimulation, known as tES, refers to a family of devices that utilize low-cost technologies and involve low-intensity currents which are safe for humans, and carry minimal risk of side effects or adverse events. Conventional approaches, which utilize fixed direct currents (tDCS) or alternating currents at a fixed oscillatory frequency (tACS), have been widely used as both a basic research tool and as a clinical intervention. In the current project, we use a custom-built device that enables near real-time current modulation triggered digitally, via software control, to allow for stimulation protocols guided by whole-brain individualized neural modeling.
Study NCT04824872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: dasiglucagon SC, high dose
Study NCT04824872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo for dasiglucagon
Study NCT05240586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy, medication(prn)
Description: This is a pragmatic RCT, so the physicians will choose the type and time of physical therapy according to participants' conditions. According to clinical judgment, clinicians can prescribe analgesics and muscle relaxants if necessary.
Study NCT06400563 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRg-NIRS
Description: The trial tests the investigator designed and developed Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) imaging system for breast cancer detection. The wearable NIRS imaging system uses 8 flex circuit strips, each with six photo-detectors (PDs) and six source fibers, that are ready to attach to a breast radially by using an adhesive nipple cover and breast tape.
Study NCT05311085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)
Study NCT05311085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine delivered via an e-cigarette
Description: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Study NCT05311085 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine plus nicotine delivered via an e-cigarette
Description: Cytisine: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)~Nicotine e-cigarette: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Study NCT05089305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone plasma
Description: Patients will be provided with an ion-laden cold atmospheric plasma administration equipment from the company Fulgur Vitae Model 9000, they will also be given the necessary indications, as well as recommendations on the use of the equipment, which they must use for 5 minutes three consecutive times a day, every 6 hours, for two weeks. They will also be provided with an atmospheric oxygen meter, with the indication to keep the ppb below 0.07. You must record in your diary the start time, end and eventualities (in case of presenting them).
Study NCT05646771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner support
Description: Remotely delivered, partner-supported weight management counseling delivered in group visits every two weeks over 14 weeks (8 sessions)